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Exercise or acute stress can exert significant effects on immune system as well as cardiovascular and respiratory systems through
catecholamines. In this study, we investigated effects of norepinephrine (NE), a catecholamine neurotransmitter on human immunodeficiency
virus type-1 (HIV-1) infection. NE inhibited in vitro HIV-1 infection of peripheral blood mononuclear cells (PBMC) from healthy donors and ex
vivo HIV-1 replication in patients’ PBMC. In transient expression assays, NE downregulated HIV-1 long terminal repeat, but site-directed
mutagenesis on NF-nB-binding sites or cotreatment with H89 (a protein kinase A inhibitor) abrogated the NE-mediated effect. Gel-shift assays
showed suppression of NF-nB activity in NE-treated cells. NE increased cytoplasmic levels of InB-a, a natural inhibitor of NF-nB. Thus, NE
apparently inhibits HIV-1 infection, at least in part through NF-nB inactivation.
D 2005 Elsevier Inc. All rights reserved.Keywords: HIV-1; Norepinephrine; Catecholamines; Stress; NF-nB; Long terminal repeatIntroduction
A number of host, viral and environmental factors have
been shown to influence the pathogenesis of human immuno-
deficiency virus type-1 (HIV-1) disease. Events in daily lives
may thus have some impacts on HIV-1 infection through
interactions between those factors. Exercise as well as acute
psychological stress leads to activation of the sympathetic
nervous system (SNS), which is mediated by neurotransmitters
such as norepinephrine (NE). NE exerts not only cardiotonic
and bronchodilating actions but also anti-inflammatory effects.
A number of previous studies have demonstrated that h-
adrenergic agonists suppress production of proinflammatory
cytokines such as tumor necrosis factor-a, interleukin (IL)-1h
and IL-6 (Cole et al., 1998; Farmer and Pugin, 2000; Heneka et
al., 2003; Koff et al., 1986; Severn et al., 1992; Talmadge et al.,0042-6822/$ - see front matter D 2005 Elsevier Inc. All rights reserved.
doi:10.1016/j.virol.2005.10.002
* Corresponding author. Department of Pediatrics, Nagasaki University
Hospital, Nagasaki 852-8501, Japan.
E-mail address: hiromori@net.nagasaki-u.ac.jp (H. Moriuchi).1993; Van der Poll et al., 1994). Since the pathogenesis of HIV-
1 infection is deeply involved in immune activation, NE may
influence HIV-1 infection as well as cytokine networks. In this
study, we show that NE inhibited HIV-1 infection, at least in
part, by downregulation of NF-nB activity.
Results and discussion
NE suppresses HIV-1 replication
NE effects on HIV-1 infection were investigated in two
systems. In in vitro or acute infection system, peripheral blood
mononuclear cells (PBMC) and monocyte-derived macro-
phages (MDM) were isolated from healthy individuals, and
were infected in vitro with R5 (AD8)- or X4 (NL4-3)-HIV-1.
PBMC that had been prestimulated with anti-CD3 and anti-
CD28 antibodies were treated with NE prior to infection and
throughout the incubation period. The concentrations of NE
used in these experiments were between 10 nM and 1 AM,
since serum NE levels reach 10 nM upon activation of the SNS
(Bierhaus et al., 2003) and NE is released neuronally into the6) 167 – 173
www.e
Fig. 1. NE inhibited HIV-1 infection of PBMC or MDM. (A, B) PBMC from
a healthy donor were prestimulated with anti-CD3 and anti-CD28 antibodies
for 2 days and infected with HIV-1 AD8 (A) or HIV-1 NL4-3 (B). One set of
culture was also treated with NE (10 nM) 24 h prior to and after infection and
RT assays were performed for cell-free culture supernatants. Similar results
were obtained from 3 different donors (data not shown). (C) MDM from a
healthy donor were either untreated or treated with NE (10 nM) 24 h prior to
and after infection with HIV-1 AD8, and RT assays were performed for cell-
free culture supernatants. Similar results were obtained from 3 different
donors (data now shown).
Table 1
NE suppressed HIV-1 outgrowth by cellular activation
Patient no.
(age/gender)
Antiviral therapy Viral RNA
(copies/ml)
CD4 T cell counts
(cells/mm3)
1 (57 M) ZDV/3TC/NFV <50 802
2 (54 F) ZDV/ddC/NFV <50 432
3 (34 M) No therapy 6900 592
4 (25 M) No therapy 4400 451
ZDV, zidovudine; 3TC, lamivudine; ddC, zalcitabine; NFV, nelfinavir.
Approximately one million CD8-depleted PBMC derived from the above patients w
NE (10 nM). Maximal RT activities obtained from cell-free supernatants during 21
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shown in Fig. 1, HIV-1 replication was reduced in the presence
of 10 nM of NE, irrelevantly to HIV-1 phenotypes (R5 versus
X4) or target cells (PBMC versus MDM). Higher concentra-
tions of NE (100 nM or 1 AM) had slightly more potent anti-
HIV-1 effects, but prolonged (>1 week) exposure to NE higher
than 10 nMwas variably toxic to PBMC in trypan blue exclusion
assays and 3-(4,5-dimethylthiazol-2-yl)-2,5-dimethyltetrazo-
lium bromide (MTT) assays (data not shown); therefore, higher
concentrations were not applied to infection experiments
thereafter. In contrast, percentages (mean T SD) of viable cells
in the presence of NE (10 nM) were comparable to those in the
absence of NE (86% T 8% versus 89% T 9%).
NE effects were also investigated in PBMC derived from
HIV-1-infected individuals, some of which had been on highly
active antiretroviral therapy (HAART) (Table 1). Ex vivo
stimulation of CD8+ T cell-depleted PBMC with anti-CD3
and anti-CD28 induced endogenous HIV-1 replication; howev-
er, cotreatment with NE precluded such HIV-1 outgrowth (Table
1). Thus, NE appears to suppress HIV-1 infection in both in
vitro (acute) and ex vivo (endogenous) experimental conditions.
To demonstrate whether NE-mediated effect is specific to
HIV-1, we also tested NE effects on infection with human T-
cell leukemia virus type I (HTLV-I), another human retrovirus.
PBMC derived from asymptomatic HTLV-I carriers were
incubated in the presence or absence of NE (10 nM), and
release of HTLV-I virions into culture medium as well as
proviral load in cells was determined. NE did not suppress ex
vivo HTLV-I infection, and contrarily, did enhance it slightly
(Table 2). Therefore, NE-mediated anti-HIV-1 activity does not
appear to be a non-specific effect.
To investigate at which step(s) in the HIV replication
cycle NE exerts its influence, we performed single-round
viral replication assays using replication-incompetent lucif-
erase-reporter molecular clone NL43-Luc-RE that had
been complemented with R5-tropic (ADA), X4-tropic
(HXB2) or amphotropic (murine leukemia virus [MLV])
Env glycoprotein. Either pretreatment or post-treatment with
NE inhibited HIV-1 infection of anti-CD3/anti-CD28-stimu-
lated PBMC or MDM in physiologically relevant concentra-
tions in serum (10 nM) or the lymphoid tissue (1 AM), and
NE had similar influence on R5-tropic, X4-tropic or ampho-
tropic virus (Figs. 2A–B).RT activity (cpm/Al)
No stimulation Anti-CD3/CD28 Anti-CD3/CD28 + NE
<40 224 <40
<40 333 <40
<40 1264 168
<40 658 <40
ere incubated in the presence or absence of anti-CD3 and anti-CD28 antibody T
-day culture period are shown.
Fig. 2. NE inhibited HIV-1 infection at post-entry step(s). (A, B) Either
pretreatment or post-treatment with NE inhibited HIV-1 infection. PBMC
prestimulated with anti-CD3 and anti-CD28 (A) or MDM (B) from healthy
donors were incubated with HIV-1 NL4-3-Luc-RE complemented with the
indicated Env glycoprotein. Where indicated, the cells were treated with 10 nM
or 1 AM of NE for 24 h prior to infection (Pre) or immediately after infection
(Post). The data shown are representative of three independent experiments
from separate donors yielding similar results, as the mean (TSD) of triplicate
determinations. Statistically significant differences between control and NE
treatment are indicated by *P < 0.05. (C) NE had little effect on HIV-1 entry
into cells. PBMC prestimulated with anti-CD3 and anti-CD28 or MDM from
healthy donors were infected with the indicated viruses, and HIV-1 proviral
loads were quantified by real-time PCR 24 h after infection. The data shown are
representative of three independent experiments from separate donors yielding
similar results, as the mean (TSD) of triplicate determinations. Statistically
significant differences between control and NE were not obtained.
Table 2
NE slightly enhanced HTLV-I replication
Patient no. Proviral load (copies/100 PBMC) p19 (pg/ml)
No stimulation NE (10 nM) No stimulation NE (10 nM)
1 0.24 0.30 65 80
2 0.12 0.29 <25 62
3 0.082 0.19 <25 <25
4 0.82 0.91 286 342
Approximately one million PBMC were incubated in the presence or absence
of NE (10 nM). Cell-free culture supernatants were collected for p19 assays,
and DNAwas extracted from cell pellets for real-time PCR of HTLV-I provirus.
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cycle NE exerts its influence, we quantified HIV-1 proviral
DNA loads 24 h after infection by real-time PCR. Pretreatment
of PBMC or MDM with NE had little effect on HIV-1 proviral
DNA loads in those experiments (Fig. 2C), indicating that NE
could not inhibit HIV-1 entry into cells. Furthermore, NE
treatment had little effects on cell surface expression of CD4,
CCR5 or CXCR4 (data not shown). Those results suggested
that post-entry step(s) are involved mostly in NE-mediated
suppression of HIV-1 infection.
NE downregulates HIV-1 long terminal repeat (LTR) promoter
To investigate mechanisms whereby NE inhibits HIV-1
infection, we tested NE effects on HIV-1 transcription, one of
the most critical post-entry steps of viral replicative cycle.
NE downregulated HIV-1 LTR activity in either cell type
(Figs. 3A–B; data not shown), and deletion of NF-nB-binding
sites, but not of SP1-binding sites abrogated the NE-mediated
effect (Figs. 3A–B).
NE-mediated downregulation of HIV-1 LTR involves inhibition
of NF-jB activity
Since the aforementioned results suggested that NF-nB-
binding sites were required for NE-mediated downregulation of
HIV-1 LTR activity, NF-nB activity was determined by gel-
mobility shift assay in nuclear extracts from NE-treated or
untreated THP-1 cells. THP-1 cells had constitutional NF-nB
activity (formation of p50/p65 heterodimer) (Fig. 3C), which
was enhanced by stimulation with phorbol 12-myristate 13-
acetate (PMA) (Fig. 3D); however, NE treatment markedly
suppressed p50/p65 heterodimer formation in a dose-dependent
manner (Figs. 3D–E). In contrast, NE had no or little effect on
SP1 activity (Fig. 3D).
Inhibition of NF-nB activity could result either from
competition of NF-nB-binding sites on HIV-1 LTR with other
transcription factor(s) or from the regulation by its natural
inhibitor, InB-a. If the former postulation was the case, gel-
mobility shift assays should have shown formation of a novel
complex on the NF-nB element. However, since we only
observed diminishment of NF-nB complex, not formation of a
novel complex, downregulation of NF-nB activity by InB-a is
more likely. To verify this postulation, two experiments were
done. First, transient expression assays were performed in thepresence of NE T H89, a protein kinase A (PK-A) inhibitor. It
has been shown that signaling of NE or other h-agonists via h-
adrenergic receptor is mediated by PK-A, and that PK-A
inhibitors prevent such activity. As expected, NE-mediated
downregulation of HIV-1 LTR was significantly neutralized by
H89 (Fig. 3F). Second, Western blot analysis was performed to
determine cytoplasmic InB-a levels inTHP-1 cells that had
been untreated or treated with NE T H89. As shown in Fig. 3G,
NE treatment increased cytoplasmic InB-a levels, but H89
counteracted NE. Those results suggested that NE down-
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nB activity.
In this study, we have shown that NE inhibited HIV-1
replication in both acute and endogenous infection systems,
and in both PBMC and MDM. Our results also suggested that
downregulation of NF-nB activity was involved in NE-
mediated anti-HIV-1 effect.
NE effects on NF-nB activity have been controversial in the
previous reports. While several studies demonstrated that NE
increases expression of I-nBa, which inhibits NF-nB activity
(Farmer and Pugin, 2000; Gavrilyuk et al., 2002; Heneka et al.,
2003), a recent study has shown that NE induces NF-nB activity
(Bierhaus et al., 2003). The reason why NE and/or other
catecholamines apparently mediated quite different effects on
NF-nB activity is unknown. The inhibitory effect was demon-
strated in THP-1 cells (Farmer et al., 2000; this study), PBMC
(this study), astrocytes (Gavrilyuk et al., 2002) or brain tissue
(Heneka et al., 2003); induction of NF-nB activity was shown in
PBMC and THP-1 cells (Bierhaus et al., 2003). Therefore, such
discrepancy cannot be explained by difference in cell types
tested. Although our study suggested that PK-A-mediated NE
signaling increased I-nBa levels, more precise molecular
mechanisms remain obscure. Further studies are needed to
clarify the apparent controversy and to define more detailed
cellular and molecular mechanisms. We are currently investi-
gating them.
It may be difficult to precisely determine net effects of
exercise or acute stress on HIV-1 infection, since a number of
factors are involved in those conditions. Although we have
demonstrated that NE, one of the mediators involved in exercise
or acute stress, inhibited HIV-1 infection, we do not believe that
adequate burden of stress simply leads to modulation of HIV-1
replication in infected individuals. However, it may be
worthwhile investigating potential benefit of exercise in HIV-
1-infected individuals, since exercise induces the SNS activity
but probably not other detrimental effects observed in stress
reactions (Cole and Kemeny, 1997). In this regard, it has been
reported that NE response to stress is blunted in HIV-1-infected
individuals (Kumar et al., 1991), and that a cerebrospinal fluid
catecholamine metabolite is lower in AIDS patients (Lasson et
al., 1991). In addition, Cole et al. (2001) have recently shown
that high autonomic nervous activity is associated with impairedFig. 3. NE downregulated HIV-1 LTR activity through inhibition of NF-nB activity.
involved in the NE-mediated effect. PBMC (A) or MDM (B) were transfected with
with NE (10 nM) for 24 h, and harvested for luciferase assays 2 days after transfecti
less than 3 (data not show). The data shown are representative of three independent
triplicate determinations. Statistically significant differences between control and NE
cells. Nuclear extracts were prepared from THP-1 cells, and gel-mobility shift assays
binding sites as a probe (Moriuchi and Moriuchi, 2004a, 2004b). Where indica
Identification of protein–DNA complexes was indicated. (D, E) Inhibition of NF-n
treated with NE (10 nM or 1 AM) or PMA before harvest for nuclear extract preparat
NF-nB-binding sites or SP1-binding sites. Similar results were obtained in nuclear e
mediated inhibition of NF-nB activity involves PK-A pathway. (F) Transient expres
were untreated or treated with NE (1 AM) T H89 (10 AM), and cell lysates were teste
experiments from separate donors yielding similar results, as the mean (TSD) of tripli
treatment are indicated by *P < 0.05. (G) Western blot analysis. Cell lysates from un
or THP-1 cells treated with both NE and H89 (10 AM) (lane 3) were analyzed by Wes
analyzed for actin (lanes 4–6).response to HAART in HIV-infected individuals. Thus, it might
be possible that individuals with high autonomic nervous system
activity may be somehow different from those with low activity
in their immunological activity or drug metabolism, and that
HIV-1 infection itself may lead to autonomic dysfunction.
Further investigations are needed to clarify these issues.
Materials and methods
In vitro or acute HIV-1 infection experiments
PBMC were isolated from healthy individuals, and propa-
gated as described previously (Moriuchi et al., 1998b). Mono-
cytes were isolated from PBMC by sorting CD14+ cells with
AutoMACS (Moriuchi and Moriuchi, 2004b), and monocyte-
derived macrophages (MDM) were propagated as described
previously (Moriuchi et al., 1998b). R5 (AD8)- andX4 (NL4-3)-
HIV-1 stocks were propagated by transfecting 293T cells with
the corresponding plasmids (Moriuchi et al., 1998b). PBMC that
had been prestimulated with anti-CD3 and anti-CD28 antibodies
(1 Ag/ml each) for 2 days, or 7-day-old MDM, were treated with
NE (Sigma Chemical Co., St. Louis, MO) 24 h prior to infection
and throughout the incubation period. Cell-free culture super-
natants were collected every 3 days for reverse transcriptase
(RT) assays (Moriuchi et al., 1998a).
Ex vivo or endogenous HIV-1 infection experiments
PBMC were isolated from HIV-1-infected patients outlined
in Table 1, and CD8+ T cells were depleted as described
previously (Moriuchi et al., 1998a). Approximately one million
CD8-depleted PBMC were incubated in RPMI-1640 with 10%
fetal bovine serum in the presence or absence of anti-CD3 and
anti-CD28 antibody (1 Ag/ml each) T NE (10 nM). Cell-free
supernatants were collected every 3 days until day 21, and tested
for RT activity.
Ex vivo or endogenous HTLV-I infection experiments
PBMC were isolated from asymptomatic HTLV-I carriers,
and approximately one million PBMC were incubated in RPMI-
1640 with 10% fetal bovine serum in the presence or absence of(A, B) NE downregulated HIV-1 LTR, and NF-nB-binding sites are apparently
the indicated reporter plasmid along with pSV2-Tat, either untreated or treated
on. Arbitrary light units of promoter-less pGL2-basic transfectants were always
experiments from separate donors yielding similar results, as the mean (TSD) of
treatment are indicated by *P < 0.05. (C) Constitutive NF-nB activity in THP-1
were performed using an oligonucleotides corresponding to HIV-1 LTR NF-nB-
ted, control serum or antibodies to p50 or p65 were added to the reaction.
B, but not SP1 in NE-treated THP-1 cells. THP-1 cells were either untreated or
ion. Gel shift assays were performed using probes corresponding to HIV-1 LTR
xtracts of PBMC derived from 3 different donors (data not shown). (F, G) NE-
sion assays. THP-1 cells were transfected with pGL-HIV-1-LTR and pSV2-Tat,
d for luciferase activity. The data shown are representative of three independent
cate determinations. Statistically significant differences between control and NE
treated THP-1 cells (lane 1), THP-1 cells treated with NE (1 AM) alone (lane 2)
tern blotting for cytoplasmic InB-a levels. The same set of cell lysates were also
M. Moriuchi et al. / Virology 345 (2006) 167–173 171NE (10 nM) for 7 days. Assays of p19 antigen levels in cell-free
supernatants and of proviral DNA in PBMC were performed as
described previously (Moriuchi and Moriuchi, 2004a).
Single-round viral replication assays
Replication-incompetent luciferase-reporter molecular clone
NL43-Luc-RE was complemented with R5-tropic (ADA),X4-tropic (HXB2) or amphotropic (murine leukemia virus
[MLV]) Env glycoprotein by cotransfecting 293T cells with
plasmids encoding the corresponding Env glycoproteins
(Moriuchi et al., 1998b). Anti-CD3/anti-CD28-prestimulated
PBMC or MDM were either untreated or treated with NE (10
nM) for 24 h, infected with those virus stocks for 3 h, and
infectivity was estimated by luciferase assays that were
performed 48 h after infection (Moriuchi et al., 1998a).
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PBMC that had been prestimulated with anti-CD3 and anti-
CD28 antibodies or MDM were untreated or pretreated with
NE (1 AM) for 24 h before infection with the indicated viruses.
The infected cells were extensively washed 4 h after, and
harvested 24 h after infection, RNA-free DNA was extracted,
according to manufacturer’s instruction (QIAamp DNA Mini
Kits, QIAGEN K.K., Tokyo, Japan) and real-time quantitative
PCR for HIV-1 proviral DNA of gag region was performed as
described previously (Hoshino et al., 2004).
Cytotoxicity tests
Viability of cultured cells was assessed with trypan blue
exclusion assays or 3-(4,5-dimethylthiazol-2-yl)-2,5-dimethyl-
tetrazolium bromide (MTT) assays after NE treatment,
according to the manufacturer’s instructions (the CellTiter-
Blue Cell Viability Assay, Promega K.K., Tokyo, Japan).
Plasmids and transfection
Plasmid pGL-HIV-1-LTR contains HIV-1 long terminal
repeat (LTR) from HXB2 strain in pGL2-basic (Promega,
Madison, WI) backbone. NF-nB and SP1 binding sites on HIV-
1 LTR were deleted in plasmids pGL-HIV-1-LTRDNF-nB and
pGL-HIV-1-LTRDSP1, respectively (Margolis et al., 1992).
Transfection of PBMC and THP-1 cells was performed by
electroporation (Moriuchi et al., 1997), and MDM were
transfected by modified calcium phosphate method (Moriuchi
et al., 1994).
Nuclear extracts, antibodies and gel-mobility shift assays
Nuclear extracts were prepared from THP-1 cells untreated
or treated with NE for 60 min or PMA for 15 min (Sigma
Chemical Co., St. Louis, MO), and gel-mobility shift assays
were performed, as described previously (Moriuchi et al.,
1997). Antibodies to p50 and p65 were kindly provided by U.
Siebenlist (National Institutes of Allergy and Infectious
Diseases, Bethesda, MD).
Western blotting
THP-1 cells were untreated or treated with NE T H-89 (10
AM) (Sigma Chemical Co., St. Louis, MO) for 60 min, and
lysed in RIPA buffer (10 mM Tris–HCl [pH 8.0], 100 mM
NaCl, 1 mM EDTA, 1% NP-40, 0.5% deoxy cholate, 0.1%
SDS and 100 Ag/ml phenylmethylsulfonyl fluoride). Lysates
from 5  105 cells were loaded in each lane, separated by SDS-
PAGE (8% acrylamide-bis-acrylamide gel) and electrotrans-
ferred onto a nitrocellulose membrane (0.45 Am). InB-a or
actin was detected with rabbit anti-human InB-a antibody
(Santa-Cruz Biotechnology, Santa Cruz, CA) or rabbit anti-
actin antibody (SIGMA-ALDRICH Japan, Tokyo, Japan),
mouse anti-rabbit horseradish peroxidase-conjugated second-
ary antibody (Amersham Biosciences, Piscataway, NJ) andenhanced chemiluminescence reaction with ECL Plus Western
Blotting Detection System (Amersham Biosciences).
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